先声药业新一代抗VEGF单抗“苏维西塔单抗”获批上市

医药魔方Info
Jul 02, 2025

7月2日,NMPA官网显示,先声药业的苏维西塔单抗获批上市,联合化疗用于含铂化疗治疗失败的复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。苏维西塔单抗是新一代重组人源化抗血管内皮生长因子(VEGF)单抗,可选择性地与人VEGF结合并阻断其生物活性,减少肿瘤血管的生成并抑制肿瘤生长,在临床前模型及早期临床研究中展现出良好的抗肿瘤活性和可控的安全性。2024年1月,由中国医学科学院肿瘤医院吴令英教授牵头的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10